{"id":"orazamide","rwe":[],"tags":[{"label":"orazamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Hepatic failure","category":"indication"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aicamin","offLabel":[],"synonyms":["aicamin","orazamid","orazamide orotate","orazamide"],"timeline":[],"approvals":[],"brandName":"Aicamin","ecosystem":[{"indication":"Hepatic failure","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"orazamide","explanation":"Imagine your liver as a factory that breaks down waste and makes energy for your body. Aicamin helps the liver factory work more efficiently, but how it does this is not yet fully understood. It may help reduce damage to liver cells or improve the way they function.","oneSentence":"Aicamin works by interacting with cellular processes to help manage hepatic failure.","technicalDetail":"The exact mechanism of action of Aicamin is unknown, but it is believed to involve modulation of cellular processes, potentially through interaction with specific molecular targets."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1994","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=orazamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:10:49.681806","biosimilars":[],"competitors":[],"genericName":"orazamide","indications":{"approved":[{"name":"Hepatic failure","source":"DrugCentral","snomedId":59927004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"CLY9MRR8FV","INN_ID":"2957","UMLSCUI":"C0069595","KEGG_DRUG":"D08298","DRUGBANK_ID":"DB06143","PDB_CHEM_ID":"5AC","PUBCHEM_CID":"167459","SECONDARY_CAS_RN":"2574-78-9","MESH_SUPPLEMENTAL_RECORD_UI":"C000259"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Aicamin (orazamide) is a small molecule drug in the orazamide class, developed for the treatment of hepatic failure. Its exact mechanism of action is unknown, but it is believed to work by modulating certain cellular processes. Aicamin is not FDA-approved, and its commercial status is unclear. Further research is needed to fully understand its safety and efficacy. As a result, it is not widely available or prescribed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}